NCT07430007Recruiting
Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.
Effect of a Tailored Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass in Overweight and Obese Patients. The MOVE-AF Ran-domized Clinical Trial
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited. The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 158 (estimated)
- First submitted
- 21 Jan 2026
- Start date
- 30 Oct 2025
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of Eastern Finland
- Diseases
- Obesity, Atrial fibrillation
- NCT number
- NCT07430007
What you commit to
- Study type: Interventional
- Planned participants: 158
- From 30 Oct 2025 to the primary completion date, 31 Dec 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in other lifestyle or drug weight reduction trials
- Recent joint or back surgery within the past 6 months
Other illness
- Unstable angina pectoris or acute coronary syndrome within the past 3 months
- Severe valvular heart disease or planned cardiac surgery
- Severe heart failure (NYHA class IV) or severe angina (CCS class IV)
- Unstable coronary artery disease or recent myocardial infarction
- Severe pulmonary disease limiting exercise capacity
- Active malignancy
- Autoimmune or systemic inflammatory diseases
- Severe renal or hepatic failure
- Memory disease or significant cognitive impairment
- Unstable psychiatric condition
- Contraindications to exercise testing or training, including cardiac symptoms or cardiovascular symptoms, making exercise unsafe
- Any condition judged by investigators to make participation unsafe or infeasible
Lab values
- Significant left ventricular dysfunction (ejection fraction \<30%)
Other
- Permanent atrial fibrillation
- Continuing back or joint pain symptoms and inability to take part in individualized exercise training
- Pregnancy or breastfeeding
- Participation in another interventional study
Who the study is looking for
- Age 18-75 years
- Body mass index (BMI) ≥27 kg/m²
- Documented atrial fibrillation (paroxysmal or persistent)
- Ability to participate in exercise training and follow study procedures
- Access to a smartphone or device enabling rhythm monitoring
- Provides written informed consent
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Nova of Central Finland Coordinator of this site? Confirm its status | Jyväskylä | Finland | Recruiting |
| Kuopio University Hospital Coordinator of this site? Confirm its status | Kuopio | Finland | Not yet recruiting |
| University Of Eastern Finland Coordinator of this site? Confirm its status | Kuopio | Finland | Not yet recruiting |
| Tampere University Hospital Coordinator of this site? Confirm its status | Tampere | Finland | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.